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Summary In this paper, we discuss the reasons why we urgently need a point-of-care (POC) CD4 test, elaborate the
problems we have experienced with the current technology which hampers CD4-count coverage and
highlight the ideal characteristics of a universal CD4 POC test. It is high-time that CD4 technology is
simpliﬁed and adapted for wider use in low-income countries to change the current paradigm of
restricted access once and for all.
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Introduction
Korpo is an ill HIV-positive mother who has walked for
over ﬁve hours on a hot and humid day to get to a
comprehensive health centre in a remote corner of north-
western Liberia. The terrain has been difﬁcult as there are
no paved roads, and public transport is almost non-
inexistent and anyway unaffordable. The clinician tells her
that she will need a blood test - the enumeration of the
absolute numbers of T helper cells (commonly referred to
as the CD4 count) - to make a decision on whether or not
she can start antiretroviral treatment (ART). A blood
specimen is collected and sent away on a motorcycle to a
distant off-site laboratory. Korpo is told to return 2 weeks
later to get the result.
In low-income countries, most health care workers in
health centres and even in district hospitals who wish to
order a CD4 test are faced with the challenge of not only
transporting the blood specimen to an off-site laboratory
but also getting the CD4 result back to the patient. There
are the many additional problems, of blood specimens
being damaged or unsuitable for testing as a result of
delays in samples reaching the CD4-count laboratory, of
machine malfunctions as a result of poor maintenance or
breakdown and of lack of reagents owing to stock-outs or
ﬁnancial constraints. For the patient, getting a CD4 test
result often means repeated visits to the health facility,
leading to delays in accessing ART. By the time, the result
is ﬁnally available, the patient is often too sick to return to
the clinic. Such individuals are frequently impossible to
ﬁnd again and end up being declared lost to follow-up
(Losina et al. 2010; Tayler-Smith et al. 2010). This sce-
nario is typical of low-income countries where 90% of the
world’s HIV⁄AIDS population reside (WHO 2009). The
core of the problem is that current CD4 technology is too
sophisticated and inappropriate for the context in which it
is being used.
In this paper, we discuss the reasons why we urgently
need a point-of-care (POC) CD4 test, elaborate on the
problems we have experienced with the current technology
which hampers CD4-count coverage, and we highlight the
ideal characteristics of a universal CD4 POC test.
Why do we need a POC CD4 test for low-income
countries?
There are a number of reasons why a POC CD4 count is
urgently needed in low-income countries (Table 1). First,
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count is no longer required for individuals in WHO clinical
stage 3 or 4, individuals in stages 1 and 2 need to have a
CD4 count <350 cells⁄mm
3 to be eligible for ART (WHO
2010). Thus CD4 testing is the gateway for identifying
individuals in WHO stage 1 and 2 who need ART.
Second, access to a CD4 count is important to start ART
early, i.e. before the patient is too sick. Earlier or so-called
‘‘upstream’’ ART access may reduce individual mortality,
mother-to-child transmission of HIV and the incidence of
HIV-associated tuberculosis (TB). A recent study from
Haiti (Severe et al. 2010) showed a 75% reduction in
mortality and a 50% reduction in TB incidence associated
with starting ART earlier. On the ground, there are huge
gaps in access to CD4 testing countrywide. CD4 counting
facilities remain laboratory-based with either standard ﬂow
cytometers from Beckton Dickinson or Beckman Coulter
or newer, simpler machines from Partec and others. Many
existing laboratory instruments end up ofﬂine or without
reagents to carry out the diagnostic testing (Malkin &
Keane 2010). In Malawi in mid-2010, of 396 ART delivery
sites of which 52(13%) had a CD4 cytometer, only
42(11%) had a functional CD4 machine (MOHP 2010).
Thus, only 1 in 10 sites had a functioning CD4 cytometer.
Over the period 2009–2010, there was progressive stag-
nation in CD4 capacity associated with machine break-
downs (Table 2).
Third, a CD4 count is the pivotal test to decide how to
implement prevention of mother-to-child HIV transmission
(PMTCT) for HIV-infected women. The recent 2010
PMTCT guidelines recommend two key approaches:
lifelong ART for HIV-infected women in need of treatment
for their own health (if the CD4 count is below
350 cells⁄mm
3) and ARV prophylaxis to prevent MTCT
during pregnancy, delivery, and breast feeding for HIV-
infected women not in need of treatment (if the CD4 count
is above 350 cells⁄mm
3) (WHO 2010). However, in
Malawi, where 454 facilities countrywide provide PMTCT
to 151 750 enrolled pregnant women, only 5338 (57%) of
the 9286 HIV-positive women were assessed for ART
eligibility (MOHP 2010). This lack of coverage is not
unique to Malawi, since in 2008 only one-third of the 1.4
million HIV-positive pregnant mothers in low- and middle-
income countries (90% of the world’s burden) were
assessed for ART eligibility (WHO 2009).
Fourth, WHO clinical staging is a clinical skill. It
requires clinical acumen and time, both of which are
lacking in low-income countries because of the limited
numbers of clinicians (Philips et al. 2008). Recent evidence
Table 1 Reasons why a point-of-care (POC) CD4 test is required in low-income countries
Reasons Potential beneﬁts
1. To assess eligibility for ART CD4 testing will help identify PLHIV in WHO clinical stage 1 and 2 who are eligible
for ART
2. To start ART earlier Earlier access to ART reduces mortality, incidence of tuberculosis and mother-to-child
transmission of HIV
3. To improve PMTCT uptake PMTCT sites will be able to implement early initiation (at 14 weeks) with the appro
priate WHO PMTCT regimen.
4. To simplify ART at the primary care level A POC CD4 test will reduce dependence on clinical acumen and the need for WHO
staging. This will increase the decision-making power and numbers initiated on ART
by nurses and other health workers
5. To enhance task-shifting ART eligibility assessments could be carried out at peripheral health facilities and at the
community level.
Early referral and earlier ART initiations could be promoted.
6. To reduce early attrition from programmes Reduced visits and waiting time for patients would foster patient retention in care
Possibility of offering an HIV test+ POC CD4 test as a ‘‘one-stop serial package’’ to
promote immediate decision-making
PLHIV, Person living with HIV; ART, Antiretroviral treatment; WHO, World Health Organization; PMTCT, Prevention of mother-to-
child transmission of HIV.
Table 2 Evolution of CD4 testing capacity at antiretroviral








Quarter 2, 2009 52 47 41 171
Quarter 3, 2009 52 47 43 882
Quarter 4, 2009 52 44 53 017
Quarter 1, 2010 53 42 43 343
Quarter 2, 2010 52 41 44 841
Source: Adapted from reference ‘‘MOHP 2010’’.
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CD4 counting over WHO staging for ART initiation in
pregnant women (Carter et al. 2010). A POC CD4 test
would simplify ART delivery at the primary level by
reducing dependence on clinical acumen and thereby
increase the numbers of patients initiated on ART by
nurses and other health workers (Philips et al. 2008;
Zachariah et al. 2009).
Fifth, with ART scale-up, there is a need to enhance
decentralisation and task-shifting. A POC CD4 test will
favour ART eligibility assessments at remote peripheral
facilities and at community level (Zachariah et al. 2009).
This is likely to have a positive inﬂuence on early referrals
and early initiation of ART.
Finally, current CD4 testing is associated with the need
for repeated patient visits and long waiting times which
constitute a heavy burden for patients. This is an important
reason for programme attrition and providing a POC CD4
test would help to limit this problem (Bassett et al. 2010;
Losina et al. 2010; Tayler-Smith et al. 2010). The ideal
scenario would be to offer an HIV test and a POC CD4 test
in a one-stop package as this would rationalize the visit
schedule as well as promote immediate decision-making on
management.
Although CD4 counts have been recommended for ART
monitoring (WHO 2010), a study in South Africa showed a
low positive predictive value (37%) compared to a viral
load test (Mee et al. 2008). Similarly, in a programme
setting in Mozambique(Maldonado et al. 2009), only 33%
of patients with detectable viral loads had clinical and
immunological signs of failure implying that 7 in 10 such
patients would be missed without a viral load test. The
DART study in Uganda and Zimbabwe on routine versus
clinically driven laboratory monitoring of ART in Africa
showed that CD4 cell count monitoring might be useful
from the second year on ART to guide the switch to
second-line treatment (Mugyenyi et al. 2010). However,
mistakes are made with this approach and evidence is now
strong to support the use of a cheap point-of-care viral load
test to identify early viral failure and limit the emergence of
resistance (Gupta et al. 2009).
Problems with traditional non-POC CD4 technology
hampering CD4 coverage
In our experience, the main problems hampering CD4
coverage in low-income countries are linked to available
technology, health facility logistics and patient factors.
Table 3 Characteristics of a universal point-of-care CD4 test for low-income countries
Characteristic Rationale
Simple to use (dip stick⁄lateral ﬂow i.e. HIV
test like preferable, no electronic instrumentation)
Important for scaling-up access to CD4 testing
Will permit task-shifting and use by unspecialized staff
Complex electronic instrumentation will require maintenance and increase
capital outlay.
Maintenance of electronic instruments is difﬁcult to implement in low-income
settings
Use non-venous blood Phlebotomy may not be available for venous blood collection
Finger-prick or other capillary blood source will allow task-shifting and
decentralization.
Easy to read Will permit task-shifting and use by unspecialized staff
Robust⁄reliable Avoid the need for repeat testing
Reduce per person test costs.
Not cold chain dependent⁄ withstands
hot climates of up to 40  C
Reduce the burden of cold-chain logistics
Reduces waste
Long shelf life (at least 15 months) Delays between procurement and supply need to be taken into account
Cold chain storage not always possible.
Short test processing time (about 10 min) Minimize patients waiting time
Avoids the need for batch testing
Relatively cheap ($1–2 US Dollars⁄test) Ensure affordability for scaling-up at country level.
Material waste can be disposed easily and safely Avoid exposure to infectious waste material
Quality assurance. The test must be adaptable to a
quality assurance programme
Quality assurance ensures tests are functioning normally and results are
trustworthy.
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regular maintenance, supervision and stocks of reagents.
The instruments themselves are very costly. Importantly,
these machines have to be placed in central locations
(district or tertiary hospitals) making them practically
inaccessible to distant rural communities. They require
skilled staff who are already overworked or unavailable.
Health staff shortages and especially shortages in medically
trained staff (nurses, medical assistants) often result in
tasks being shifted to trained non-medical staff. There are a
number of so-called POC CD4 count devices, bench-top
machines of little help in increasing access to CD4 count
tests. At country level, quality assurance issues and
ensuring adherence to maintenance contracts in the
medium- to longer term are also often unresolved. In
summary, what we have is inappropriate CD4 technology
that is inaccessible for rural communities in low-income
countries.
From a health facility perspective, because of the scale-
up efforts, there are often too many CD4 tests to be carried
out in the face of limited capacity for CD4 testing,
particularly in high-prevalence contexts. Blood is trans-
ported from peripheral health facilities to an off-site
laboratory which proves cumbersome, expensive and
impractical. Unavoidably, blood samples are picked up too
late or are improperly transported and the results deemed
unreliable. Blood collection in tubes for transport requires
dedicated staff time, and there is a risk of wrong labelling
or mixing-up of results. In summary, health facility
logistics are complex and often unsustainable.
Finally, from the patient perspective, non-POC CD4
technology often means repeated visits to the health facility
which in turn means repeated travel, time and costs. This
burden often results in patients being lost to attrition
(Losina et al. 2010; Tayler-Smith et al. 2010).
Characteristics of a universal POC-CD4 test
The ideal characteristics of a universal POC CD4 test are
summarized in Table 3. It should be: (i) a dip-stick test or a
test similar to the HIV rapid which can be performed on
ﬁnger-prick whole blood; (ii) simple to perform and easy to
read; (iii) reliable, not cold chain dependent, with a long
shelf life and relatively cheap (<$5). The new PIMA
Alere
TM PIMA POC CD4 test has produced promising
results (Mtapuri-Zinyowera et al. 2010), but instrument
costs are signiﬁcant (>$6000) and throughput is relatively
low at 10–15 CD4 tests per day. (iv) Finally, a test that
avoids the need for electronic instrumentation, whether a⁄c
power or battery operated, would be highly advantageous.
Electronic instruments are often ofﬂine, insufﬁciently
maintained and lacking spare parts or batteries.
Conclusion
Over recent years, there have been a number of interesting
and laudable developments in the ﬁeld of simplifying CD4
technology, for example the Alere
TM PIMA CD4 test
(Mtapuri-Zinyowera et al. 2010). Further, very promising
POC tests are emerging from the CD4 Initiative (CD4
Initiative 2010), particularly the instrument-free POC CD4
test from Zyomyx, Inc. Independent evaluations in London
with samples from an HIV outpatient clinic have shown
high correlation with ﬂow cytometry (data not shown).
Field trials are scheduled for the end of 2010 for this rapid
CD4 test which produces results in <10 min.
Although these initiatives considerably improve the
potential for decentralized CD4 access, a quantum shift is
still needed to achieve greater simplicity and meet the
requirement of an ideal universal CD4 - POC test for low-
income countries. POC CD4 remains a vital entry door to
accessing ART, improving immediate decision-making,
patient management and referral, improving patient reten-
tion in care and alleviating the testing burden at centralized
laboratories. A simpliﬁed CD4 counting technology
adapted for wider use in low-income countries will change
the current paradigm of restricted access once and for all.
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